Antibodies against Clostridium difficile toxins and uses thereof

Share
Save
Discuss
Claim

Share On Facebook Share On Twitter Share By Email
Save Item
Save Item
Add to
my lists

Filing Information

  • Patent Number: US7625559
  • Application Number: US11051453
  • Filing date: 02/04/2005
  • Issue date: 12/01/2009
  • Prior Publication Data:
  • Predicted expiration date: 10/20/2026
  • Patent term adjustment: 623
Explore Your Innovation Network™ for an introduction to:

Innovation Network Your First Name:
 Last Name:
  
Already a member? Sign In
  • U.S. Classifications: 424/139.1  · 424/178.1  · 424/934  · 424/234.1  · 424/184.1  · 424/130.1  · 424/236.1  · 424/247.1  · 536/231  · 424/141.1  ·
  • International Classifications: A61K3900 · A61K39395 · A61B5055 · A61K3902 · A61K3938 · A61K3908 · C07H2102 ·
  • Related U.S. Application Data:
    RELATED INFORMATION
    The application claims priority to U.S. provisional patent application No. 60/542,357, filed on Feb. 6, 2004, and U.S. provisional patent application No. 60/613,854, filed on Sep. 28, 2004, the entire contents both of which are hereby incorporated by reference.
    The contents of any patents, patent applications, and references cited throughout this specification are hereby incorporated by reference in their entireties.
  • View document at: (opens new window):
    USPTO  ·  PAIR  ·  esp@cenet  ·  Patent Family
    * Related patent documents may or may not exist on these sites
4 Claims, 35 Drawings


Abstract

Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US5545806 GenPharm International, Inc. Lonberg et al. Aug 1996
US5569825 GenPharm International Lonberg et al. Oct 1996
US5625126 GenPharm International, Inc. Lonberg et al. Apr 1997
US5633425 GenPharm International, Inc. Lonberg et al. May 1997
US5661016 GenPharm International Inc. Lonberg et al. Aug 1997
US5770429 GenPharm International, Inc. Lonberg et al. Jun 1998
US5789650 GenPharm International, Inc. Lonberg et al. Aug 1998
US5814318 GenPharm International Inc. Lonberg et al. Sep 1998
US6214341 OraVax Thomas, Jr. et al. Apr 2001
US7151159* Christoph von Eichel-Streiber Von Eichel-Streiber et al. Dec 2006

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
WO199203918GENPHARM INTMar 1992
WO199425585GENPHARM INTNov 1994
WO199824884GENPHARM INTJun 1998
WO199912971VON EICHEL STREIBER CHRISTOPHMar 1999
WO199920304ORAVAX INCApr 1999
WO200192340IMMUNEX CORPORATIONDec 2001
WO2003092630THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESNov 2003
* cited by examiner

Other Publications

Greenspan et al. (Nature Biotechnology 17: 936-937, 1999).*
Seffernick et al (J. Bacteriology, 2001; 183: 2405-2410).*
Bowie et al. (Science, 1990, 257:1306-1310).*
Aboud, W., et al. “Pseudomembranous colitis.” Gastrointest Endosc. Aug. 2000; 52(2):234.
Adler, S., et al. “Costs of low-temperature plasma sterilization compared with other sterilization methods.” J Hosp Infect. Oct. 1998; 40(2):125-34.
Aktories, K., et al. “Rho GTPases as targets of bacterial protein toxins.” Biol Chem. May-Jun. 2000; 381(5-6):421-6.
Aldeen, W.E., et al. “Comparison of the TOX A/B test to a cell culture cytotoxicity assay for the detection of Clostridium difficile in stools.” Diagn Microbiol Infect Dis. Apr. 2000; 36(4):211-3.
Alfa, M.J., et al. “Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea.” J Clin Microbiol . Jul. 2000; 38(7):2706-14.
Anderson, R.J., et al. “Evidence for Rho protein regulation of renal tubular epithelial cell function.” Kidney Int. Nov. 2000; 58(5):1996-2006.
Aronsson, B., et al. “Enzyme-linked immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea.” J Immunol Methods. Jun. 10, 1983; 60(3):341-50.
Aronsson, B., et al. “Diagnosis and epidemiology of Clostridium difficile enterocolitis in Sweden.” J Antimicrob Chemother. Dec. 1984; 14 Suppl D:85-95.
Bacon, Ill, A.E., etal. “Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea.” Diagn Microbiol Infect Dis. Apr. 1994; 18(4):205-9.
Barbut, F., et al. “Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.” Antimicrob Agents Chemother. Nov. 1999; 43(11):2607-11.
Barroso, L.A., et al. “Nucleotide sequence of Clostridium difficile toxin B gene.” Nucleic Acids Res. Jul. 11, 1990; 18(13):4004.
Barth, H., et al. “Low pH-induced formation of ion channels by clostridium difficile toxin B in target cells.” J Biol Chem. Apr. 6, 2001; 276(14):10670-6.
Bartlett, J.G., et al. “Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia.” Am J Vet Res. Sep. 1978; 39(9):1525-30.
Bartlett, J.G., et al. “Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.” N Engl J Med. Mar. 9, 1978; 298(10):531-4.
Bartlett, J.G., et al. “Comparison of five regimens for treatment of experimental clindamycin- associated colitis.” J Infect Dis. Jul 1978; 138(1):81-6.
Bartlett, J.G., et al. “Colitis induced by Clostridium difficile.” Rev Infect Dis. Mar.-Apr. 1979; 1(2):370-8.
Bartlett, J.G. “Treatment of antibiotic-associated pseudomembranous colitis.” Rev Infect Dis. Mar.-Apr. 1984; 6 Suppl 1:S235-41.
Berdoz, J., et al. “In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells.” Proc Natl Acad Sci USA. Mar. 16, 1999; 96(6):3029-34.
Berneman, A., et al. “The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions.” Infect lmmun. Sep. 1998; 66(9):4163-8.
Bongaerts, G.P.A., et al. “Role of toxins A and B in the pathogenesis of Clostridium difficile disease.” Microb Pathog. Jul 1994; 17(1):1-12.
Boquet, P. “Bacterial toxins inhibiting or activating small GTP-binding proteins.” Ann N Y Acad Sci. 1999; 886:83-90.
Borody, T.J. ““Flora Power” —fecal bacteria cure chronic C. difficile diarrhea.” Am J Gastroenterol. Nov. 2000; 95(11):3028-9.
Borriello, S.P. “Pathogenesis of Clostridium difficile infection.” J Antimicrob Chemother. May 1998; 41 Suppl C:13-9.
Borriello, S.P., et al. “Clostridium difficile infections of the gut: the unanswered questions.” J Antimicrob Chemother. May 1998; 41 Suppl C:67-9.
Borriello, S.P., et al. “Clostridium difficile-a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis.” J Med Microbiol. Aug. 1987; 24(1):53-64.
Busch, C., et al. “Involvement of a conserved tryptophan residue in the UDP-glucose binding of large clostridial cytotoxin glycosyltransferases.” J Bio! Chem. May 5, 2000; 275(18): 13228-34.
Calderón, G.M., et al. “Effects of toxin A from Clostridium difficile on mast cell activation and survival.” Infect Immun. Jun. 1998; 66(6):2755-61.
Castagliuolo, I., et al. “Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells.” J lmmunol. Jun. 15, 1998; 160(12): 6039-45.
Castagliuolo, I., et al. “Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.” Infect lmmun. Jan. 1999; 67(1):302-7.
Castagliuolo, I., et al. “A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum.” Gastroenterology. Aug. 1996; 111(2):433-8.
Castagliuolo, I., et al. “IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum.” Am J Physiol. Aug. 1997; 273(2 Pt 1):G333-41.
Cerquetti, M., et al. “Characterization of surface layer proteins from different Clostridium difficile clinical isolates.” Microb Pathog. Jun. 2000; 28(6):363-72.
Chang, T-W, et al. “Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients.” Infect lmmun. May 1978; 20(2):526-9.
Chang, T-W, et al. “Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins.” Infect lmmun. Nov. 1978; 22(2):418-22.
Chang, T-W, et al. “Cytotoxicity assay in antibiotic-associated colitis.” J Infect Dis. Nov. 1979; 140(5):765-70.
Chaves-Olarte, E., et al. “A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins.” J Biol Chem. Apr. 16, 1999; 274(16): 11046-52.
Chaves-Olarte, E., et al. “Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells.” J Clin Invest. Oct. 1, 1997; 100(7):1734-41.
Ciesla, Jr., W.P., et al. “Clostridium difficile oxins A and B are cation-dependent UDP-glucose hydrolases with differing catalytic activities.” J Biol Chem. Jun. 26, 1998; 273(26):16021-6.
Clabots, C.R., et al. “Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.” J Infect Dis. Sep. 1992; 166(3):561-7.
Cohen, S.H., et al. “Isolation of a toxin B-deficient mutant strain of Clostridium difficile in a case of recurrent C. difficile-associated diarrhea.” Clin Infect Dis. Feb. 1998; 26(2):410-2.
Cohen, S.H., et al. “Analysis of the pathogenicity locus in Clostridium difficile strains.” J Infect Dis. Feb. 2000; 181(2):659-63.
Cooke, D.L., et al. “Nonspecific binding of Clostridium difficile toxin A to murine immunoglobulins occurs via the fab component.” Infect lmmun. May 1998; 66(5):1981-4.
Corthier, G., et al. “Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficiletoxin A.” Infect lmmun. Mar. 1991; 59(3):1192-5.
Czuprynski, C.J., et al. “Pseudomembranous colitis in Clostridium difficile-monoassociated rats.” Infect lmmun. Mar. 1983; 39(3):1368-76.
Dallas, S.D., et al. “Binding of Clostridium difficile toxin A to human milk secretory component.” J Med Microbiol. Oct. 1998; 47(10):879-88.
DeGirolami, P.C., et al. “Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A.” J Clin Microbiol. May 1992; 30(5)1085-8.
de Lalla, F., et al. “Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital.” J Antimicrob Chemother. Apr. 1989; 23(4):623-31.
DiPersio, J.R., et al. “Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease.” J Clin Microbiol.. Dec. 1991; 29(12):2724-30.
Doern, G.V., et al. “Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays.” J Clin Microbiol. Aug. 1992; 30(8):2042-6.
Donta, S.T., et al. “Effects of Clostridium difficile toxin on tissue-cultured cells.” J Infect Dis. Feb. 1980; 141(2):218-22.
EI-Gammal, A., et al. “Evaluation of the clinical usefulness of C. difficile toxin testing in hospitalized patients with diarrhea.” Diagn Microbiol Infect Dis. Mar. 2000; 36(3):169-73.
Enad, D., et al. “Is Clostridium difficile a pathogen in the newborn intensive care unit? A prospective evaluation.” J Perinatol. Sep.-Oct. 1997; 17(5):355-9.
Farrell, R.J., et al. “Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis.” Curr Top Microbiol lmmunol. 2000; 250:109-25.
Faust, C., et al. “The enzymatic domain of Clostridium difficiletoxin A is located within its N- terminal region.” Biochem Biophys Res Commun. Oct. 9, 1998; 251(1):100-5.
Fekety, R., et al. “Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.” Am J Med. Jan. 1989; 86(1):15-9.
Feltis, B.A., et al. “Clostridium difficile toxins may augment bacterial penetration of intestinal epithelium.” Arch Surg. Nov. 1999; 134(11):1235-41.
Feltis, B.A., et al. “Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes.” Shock. Dec. 2000; 14(6):629-34.
Fernie, D.S., et al. “Active and passive immunization to protect against antibiotic associated caecitis in hamsters.” Dev Biol Stand. 1983; 53:325-32.
Fiorentini, C, et al. “Clostridium difficile toxin B induces apoptosis in intestinal cultured cells.” Infect lmmun. Jun. 1998; 66(6):2660-5.
Fishwild, D.M., et al. “High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.” Nat Biotechnol. Jul. 1996; 14(7):845-51.
Frost, F., et al. “Estimated incidence of Clostridium difficile infection.” Emerg Infect Dis. Mar.-Apr. 1999; 5(2):303-4.
Genth, H., et al. “Monoglucosylation of RhoA at threonine 37 blocks cytosol-membrane cycling.” J Biol Chem. Oct. 8, 1999; 274(41):29050-6.
Genth, H., et al. “New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization.” Infect lmmun. Mar. 2000; 68(3):1094-101.
Gerding, D.N. “Treatment of Clostridium difficile-associated diarrhea and colitis.” Curr Top Microbiol Immuno. 2000; 250:127-39.
Gerding, D.N., et al. “Clostridium difficile-associated diarrhea and colitis.” Infect Control Hosp Epidemiol. Aug. 1995; 16(8):459-77.
Giannasca, P.J., et al. “Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.” Infect lmmun. Feb. 1999; 67(2):527-38.
Gilbert, R.J., et al. “Effect of purified Clostridium difficile toxins on intestinal smooth muscle. I. Toxin A.” Am J Physiol. Apr. 1989; 256(4 Pt 1):G759-66.
Gilbert, R.J., et al. “Effect of purified Clostridium difficile toxins on intestinal smooth muscle. II. Toxin B.” Am J Physiol. Apr. 1989; 256(4 Pt 1):G767-72.
Gorbach, S. L. “Antibiotics and Clostridium difficile.” N Engl J Med. Nov. 25, 1999; 341(22): 1690-1.
Gotz, V.P., et al. “Medical management of antimicrobial-associated diarrhea and colitis.” Pharmacotherapy. Mar.-Apr. 1982; 2(2):100-9.
Guerrant, R.L., et al. “How intestinal bacteria cause disease.” J Infect Dis. Mar. 1999; 179 Suppl 2:S331-7.
He, D., et al. “Clostridium difficile toxin A causes early damage to mitochondria in cultured cells.” Gastroenterology. Jul. 2000; 119(1):139-50.
Hirschhorn, L.R., et al. “Epidemiology of community-acquired Clostridium difficile-associated diarrhea.” J Infect Dis. Jan. 1994; 169(1):127-33.
Hofmann, F., et al. “Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition.” Infect lmmun. Mar. 1998; 66(3):1076-81.
Hofmann, F., et al. “Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin.” J Biol Chem. Apr. 25, 1997; 272(17):11074-8.
Johnson, S., et al. “Clostridium difficile—associated diarrhea.” Clin Infect Dis. May 1998; 26(5):1027-34.
Johnson, S., et al. “Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.” N Engl J Med. Nov. 25, 1999; 341(22):1645-51.
Johnson, S., et al. “Nosocomial Clostridium difficile colonisation and disease.” Lancet. Jul. 14, 1990; 336(8707):97-100.
Johnson, S., et al. “Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial.” Ann Intern Med. Aug. 15, 1992; 117(4):297-302.
Johnson, S., et al. “Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.” J Infect Dis. Dec. 1992; 166(6):1287-94.
Johnson, S., et al. “Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease.” Infect lmmun. Aug. 1995; 63(8):3166-73.
Just, I., et al. “Molecular mode of action of the large clostridial cytotoxins.” Cuff Top Microbiol lmmunol. 2000; 250:55-83.
Just, I., et al. “Large clostridial cytotoxins as tools in cell biology.” Curr Top Microbiol Immunol. 2000; 250:97-107.
Just, I., et al. “Glucosylation of Rho proteins by Clostridium difficile toxin B.” Nature. Jun. 8, 1995; 375(6531):500-3.
Karasawa, T., et al. “Laboratory diagnosis of toxigenic Clostridium difficile by polymerase chain reaction: presence of toxin genes and their stable expression in toxigenic isolates from Japanese individuals.” J Gastroenterol. Feb. 1999; 34(1):41-5, (Abstract).
Karlsson, S., et al. “Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids.” Microbiology. Jul. 1999; 145 ( Pt 7):1683-93.
Kato, H., et al. “Deletions in the repeating sequences of the toxin A gene of toxin A-negative, toxin B-positive Clostridium difficile strains.” FEMS Microbiol Lett. Jun. 15, 1999; 175(2): 197-203.
Kawamoto, S., et al. “Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation.” Radioqraphics. Jul.-Aug. 1999; 19(4):887-97.
Kelley, B.D., et al. “Demonstrating process robustness for chromatographic purification of a recombinant protein.” BioPharm. Oct. 1997; 36-47.
Kelly, C.P., et al. “Clostridium difficile infection.” Annu Rev Med. 1998; 49:375-90.
Kelly, C.P. “Immune response to Clostridium difficile infection.” Eur J Gastroenterol Hepatol. Nov. 1996; 8(11):1048-53.
Kim, P-H., et al. “Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters.” Infect Immun. Dec. 1987; 55(12): 2984-92.
Kink, J.A., et al. “Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.” Infect Immun. May 1998; 66(5):2018-25.
Klingler, P.J., et al. “Clostridium difficile infection: risk factors, medical and surgical management.” Dig Dis. 2000; 18(3):147-60.
Knoop, F.C., et al. “Clostridium difficile: clinical disease and diagnosis.” Clin Microbiol Rev. Jul. 1993; 6(3):251-65.
Korhonen, H., et al. “Bovine milk antibodies for health.” Br J Nutr. Nov. 2000; 84 Suppl 1: S135-46, (Abstract).
Kotloff, K.L, et al. “Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.” Infect Immun. Feb. 2001; 69(2):988-95.
Krah, D.L. “Assays for antibodies to varicella-zoster virus.” Infect Dis Clin North Am. Sep. 1996; 10(3)507-27.
Kroker, P.B., et al. “Clostridium difficile infection, hospital geography and time-space clustering.” QJM. Apr. 2001; 94(4):223-5.
Kurtz, C.B., et al. “GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.” Antimicrob Agents Chemother. Aug. 2001; 45(8):2340-7.
Lamm, M.E. “Interaction of antigens and antibodies at mucosal surfaces.” Annu Rev Microbiol. 1997; 51:311-40.
Landry, M.L., et al. “Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus.” J Clin Microbiol. May 1987; 25(5):832-5.
Leung, D.Y.M., et al. “Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.” J Pediatr. Apr. 1991; 118(4) (Pt 1): 633-7.
Libby, J.M., et al. “Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters.” Infect Immun. May 1982; 36(2):822-9.
Limaye, A.P., et al. “Pseudomembranous colitis caused by a toxin A(−) B(+) strain of Clostridium difficile.” J Clin Microbiol. Apr. 2000; 38(4):1696-7.
Lyerly, D.M., et al. “Effects of Clostridium difficile toxins given intragastrically to animals.” Infect. lmmun. Feb. 1985; 47(2):349-52.
Lyerly, D.M., et al. “Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A.” J Clin Microbio. Jan. 1985; 21(1):12-4.
Lyerly, D.M., et al. “Passive immunization of hamsters against disease caused by Clostridium difficileby use of bovine immunoglobulin G concentrate.” Infect Immun. Jun. 1991; 59(6): 2215-8.
Madan, E., et al. “Stool caproic acid for screening of Clostridium difficile.” Am J Clin Pathol. Apr. 1988; 89(4):525-7.
Mahida, Y.R., et al. “Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis.” Infect Immun. Nov. 1998; 66(11):5462-9.
Mahida, Y.R., et al. “Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment.” Gut. Mar. 1996; 38(3):337-47.
Mahida, Y.R., et al. “Migration of human intestinal lamina propria lymphocytes, macrophages and eosinophils following the loss of surface epithelial cells.” Clin Exp lmmunol. Aug. 1997; 109(2):377-86.
Mani, N., et al. “Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor.” Proc Natl Acad Sci USA. May 8, 2001; 98(10):5844-9.
Massol, P., et al. “Fc receptor-mediated phagocytosis requires CDC42 and Rac1.” EMBO J. Nov. 2, 1998; 17(21):6219-29.
Mattsson, J.G., et al. “MPS1: a small, evolutionarily conserved zinc finger protein from the protozoan Toxoplasma gondii.” FEMS Microbiol Lett. Nov. 15, 1999; 180(2):235-9.
Mayfield, J.L., et al. “Environmental control to reduce transmission of Clostridium difficile.” Clin Infect Dis Oct. 2000; 31(4):995-1000.
McFarland, L.V., et al. “Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients.” Infect Immun. Jul. 1991; 59(7):2456-62.
McFarland, L.V., et al. “Nosocomial acquisition of Clostridium difficile infection.” N Engl J Med. Jan. 26, 1989; 320(4):204-10.
McFarland, L.V., et al. “Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients.” J Infect Dis. Sep. 1990; 162(3):678-84.
McGhee, J.R., et al. “The mucosal immune system: from fundamental concepts to vaccine development.” Vaccine. 1992; 10(2):75-88.
Miller, P.D., et al. “Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore.” Cell lmmunol. Mar. 1990; 126(1):155-63.
Moncrief, J.S., et al. “Genetics of Clostridium difficile toxins.” Curr Top Microbiol Immunol. 2000; 250:35-54.
Moncrief, J.S., et al. “Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR.” J Clin Microbio. Aug. 2000; 38(8):3072-5.
Moore, R., et al. “C. difficile toxin A increases intestinal permeability and induces Cl- secretion.” Am J Physiol. Aug. 1990; 259(2 Pt 1):G165-72.
Mulligan, M.E., et al. “Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile.” Clin Infect Dis. Jun. 1993; 16 Suppl 4:S239-44.
Mylonakis, E., et al. “Clostridium difficile— Associated diarrhea: A review.” Arch Intern Med. Feb. 26, 2001; 161(4):525-33.
Nusrat, A., et al. “Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins.” Infect Immun. Mar. 2001; 69(3):1329-36.
Ohguchi, K., et al. “Effects of Clostridium difficile toxin A and toxin B on phospholipase D activation in human promyelocytic leukemic HL60 cells.” Infect Immun. Nov. 1996; 64(11): 4433-7.
Pavliakova, D., et al. “Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice.” Infect lmmun. Apr. 2000; 68(4):2161-6.
Peakman, T.C., et al. “Comparison of expression of a humanized monoclonal antibody in mouse NSO myeloma cells and Chinese hamster ovary cells.” Hum Antibodies Hybridomas. 1994; 5(1-2):65-74.
Pochapin, M. “The effect of probiotics on Clostridium difficile diarrhea.” Am J Gastmenterol. Jan. 2000; 95(1 Suppl):S11-3.
Pothoulakis, C. “Effects of Clostridium difficile toxins on epithelial cell barrier.” Ann N Y Acad Sci. 2000; 915:347-56.
Pothoulakis, C., et al. “Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins.” Am J Physiol Gastrointest Liver Physiol. Feb. 2001; 280(2):G178-83.
Pothoulakis, C., et al. “Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa.” Gastroenterology. Nov. 1986; 91(5):1147-53.
Pothoulakis, C., et al. “Purification and properties of Clostridium difficile cytotoxin B.” J Biol Chem. Jan. 25, 1986; 261(3):1316-21.
Pothoulakis, C., et al. “Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes.” J Clin Invest. Jun. 1988; 81(6):1741-5.
Qa'Dan, M., et al. “pH-induced conformational changes in Clostridium difficile toxin B.” Infect Immun. May 2000; 68(5):2470-4.
Qamar, A., et al. “Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.” Infect lmmun. Apr. 2001; 69(4):2762-5.
Reeve, R. “Two statistical methods for estimating relative potency of bioassays.” BioPharm. Jul. 2000; 54-60.
Riegler, M., et al. “Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro.” J Clin Invest. May 1995; 95(5):2004-11.
Rolland, R.M., et al. “Five spontaneous deaths associated with Clostridium difficile in a colony of cotton-top tamarins (Saguinus oedipus).” Lab Anim Sci. Oct. 1997; 47(5):472-6.
Rupnik, M., et al. “Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes.” Microbiology. Feb. 2001; 147(Pt 2):439-47.
Ryan, E.T., et al. “Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.” Infect lmmun. Ju. 1997; 65(7):2941-9.
Salcedo, J., et al. “Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.” Gut. Sep. 1997; 41(3):366-70.
Sambol, S.P., et al. “Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.” Infect lmmun. Oct. 2000; 68(10):5480-7.
Sambol, S.P., et al. “Infection of hamsters with epidemiologically important strains of Clostridium difficile.” J Infect Dis. Jun. 15, 2001; 183(12):1760-6.
Samore, M.H. “Epidemiology of nosocomial clostridium difficile diarrhoea.” J Hosp Infect. Dec. 1999; 43 Suppl:S183-90.
Sauerborn, M., The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiol Lett. Oct. 1, 1997;155(1):45-54.
Saville, W.J., et al. “Necrotizing enterocolitis in horses: a retrospective study.” J Vet Intern Med. Jul.-Aug. 1996; 10(4):265-70.
Siffert, J-C, et al. “Effects of Clostridium difficile toxin B on human monocytes and macrophages: possible relationship with cytoskeletal rearrangement.” Infect lmmun. Mar. 1993; 61(3):1082-90.
Smith, J.A., et al. “Clostridium difficile toxin A binding to human intestinal epithelial cells.” J Med Microbiol. Nov. 1997; 46(11):953-8.
Souza, M.H.L., et al. “The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B.” Immunology. Jun. 1997; 91(2):281-8.
Spencer, R.C. “Clinical impact and associated costs of Clostridium difficile-associated disease.” J Antimicrob Chemother. May 1998; 41 Suppl C:5-12.
Stubbe, H., et al. “Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers.” J Immunol. Feb. 15, 2000; 164(4):1952-60.
Surawicz, C.M., et al. “The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.” Clin Infect Dis. Oct. 2000; 31(4):1012-7.
Teasley, D.G., et al. “Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.” Lancet. Nov. 5, 1983, 2(8358):1043-6.
Thelestam, M., et al. “Cytotoxic effects of the Clostridium difficile toxins.” Curr Top Microbiol Immunol. 2000; 250:85-96.
Thelestam, M., etal. “Interaction of cytopathogenic toxin from Clostridium difficile with cells in tissue culture.” Scand J Infect Dis Suppl. 1980; (Suppl 22):16-29.
Thielman, N.M. “Antibiotic-associated colitis.” Chapter 84, 1111-26.
Tjellström, B., et al. “Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis.” Lancet. Mar. 13, 1993; 341(8846):701-2.
Toothaker, R.D., et al. “Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii.” Antimicrob Agents Chemother. Oct. 1984; 26(4):552-6.
Torres, J.F., et al. “Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.” Infect lmmun. Dec. 1995; 63(12):4619-27.
Triadafilopoulos, G., et al. “Differential effects of Clostridium difficile toxins A and B on rabbit ileum.” Gastroenterology. Aug. 1987; 93(2):273-9.
Viscidi, R., et al. “Serum antibody response to toxins A and B of Clostridium difficile.” J Infect Dis. Ju. 1983; 148(1):93-100.
Walev, I., et al. “Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O.” Proc Natl Acad Sci USA. Mar. 13, 2001; 98(6):3185-90.
Waligora, A-J, et al. “Clostridium difficile cell attachment is modified by environmental factors.” Appl Environ Microbiol. Sep. 1999; 65(9):4234-8.
Ward, S.J., et al. “Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.” Infect lmmun. Oct. 1999; 67(10):5124-32.
Ward, S.J., et al. “Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.” Infect lmmun. May 1999; 67(5):2145-52.
Warny, M., et al. “Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.” Gut. Feb. 1999; 44(2):212-7.
Warny, M., et al. “Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.” Infect lmmun. Feb. 1994; 62(2):384-9.
Warny, M., et al. “Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A.” Acta Clin Belg. 1995; 50(1):36-9.
Wedel, N., et al. “Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts.” Exp Cell Res. Oct. 15, 1983; 148(2):413-22.
Wilcox, M., et al. “Role of antibody response in outcome of antibiotic-associated diarrhoea.” Lancet. Jan. 20, 2001; 357(9251):158-9.
Wiström, J., et al. “Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study.” J Antimicrob Chemother. Jan. 2001; 47(1):43-50.
Xia, Y., et al. “Clostridium difficile toxin A excites enteric neurones and suppresses sympathetic neurotransmission in the guinea pig.” Gut. Apr. 2000; 46(4):481-6.
Barroso, Lisa A. et al., “Mutagenesis of the Clostridium difficile toxin B gene and effect of cytotoxic activity,” Microbial Pathogenesis, vol. 16:297-303 (1994).
Deng, Xiao K. et al., “Recombinant Single-Chain Variable Fragment Antibodies Directed against Clostridium difficle Toxin B Produced by Use of an Optimized Phage Display System,” Clinical and Diagnostic Laboratory Immunology, vol. 10(4):587-595 (2003).
Frey, Steven M. et al., “Localization of Two Epitopes Recognized by Monoclonal Antibody PCG-4 on Clostridium difficile Toxin A,” Infection and Immunity, vol. 60(6):2488-2492 (1992).
Spyres, Lea M. et al., “Mutational Analysis of the Enzymatic Domain of Clostridium difficile Toxin B Reveals Novel Inhibitors of the Wild-Type Toxin,” Infection and Immunity, vol. 71(6):3294-3301 (2003).
International Search Report for Application No. PCT/US2005/003725, dated Dec. 28, 2006.
* cited by examiner

Referenced By

The current document is not referenced by other documents.

Patent Family

The current document is not in a family.

Read Patent

Read patent

Independent Claims | See all claims (4)

  1. 1. A composition comprising a first monoclonal antibody, or an antigen binding portion thereof, and a second monoclonal antibody, or an antigen binding portion thereof, wherein, (a) the first antibody, or antigen binding portion thereof, comprises a heavy and light chain variable region having the amino acid sequences set forth in SEQ ID NOs:1 and 4, respectively, and (b) the second antibody, or antigen binding portion thereof, comprises a heavy and light chain variable region having the amino acid sequences set forth in SEQ ID NOs:54 and 58, respectively.